TY  - JOUR
A1  - Robin, Marie
A1  - de Wreede, Liesbeth C.
A1  - Wolschke, Christine
A1  - Schetelig, Johannes
A1  - Eikema, Diderik-Jan
A1  - Van Lint, Maria Teresa
A1  - Knelange, Nina Simone
A1  - Beelen, Dietrich
A1  - Brecht, Arne
A1  - Niederwieser, Dietger
A1  - Vitek, Antonin
A1  - Bethge, Wolfgang
A1  - Arnold, Renate
A1  - Finke, Jürgen
A1  - Volin, Liisa
A1  - Yakoub-Agha, Ibrahim
A1  - Nagler, Arnon
A1  - Poiré, Xavier
A1  - Einsele, Hermann
A1  - Chevallier, Patrice
A1  - Holler, Ernst
A1  - Ljungman, Per
A1  - Robinson, Stephen
A1  - Radujkovic, Alekxandar
A1  - McLornan, Donal
A1  - Chalandon, Yves
A1  - Kröger, Nicolaus
T1  - Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
JF  - Haematologica
N2  - Allogeneic hematopoietic stem cell transplant remains the only curative treatment for myelofibrosis. Most post-transplantation events Aoccur during the first two years and hence we aimed to analyze the outcome of 2-year disease-free survivors. A total of 1055 patients with myelofibrosis transplanted between 1995 and 2014 and registered in the registry of the European Society for Blood and Marrow Transplantation were included. Survival was compared to the matched general population to determine excess mortality and the risk factors that are associated. In the 2-year survivors, disease-free survival was 64% (60-68%) and overall survival was 74% (71-78%) at ten years; results were better in younger individuals and in women. Excess mortality was 14% (8-21%) in patients aged <45 years and 33% (13-53%) in patients aged >= 65 years. The main cause of death was relapse of the primary disease. Graft-versus-host disease (GvHD) before two years decreased the risk of relapse. Multivariable analysis of excess mortality showed that age, male sex recipient, secondary myelofibrosis and no GvHD disease prior to the 2-year landmark increased the risk of excess mortality. This is the largest study to date analyzing long-term outcome in patients with myelofibrosis undergoing transplant. Overall it shows a good survival in patients alive and in remission at two years. However, the occurrence of late complications, including late relapses, infectious complications and secondary malignancies, highlights the importance of screening and monitoring of long-term survivors.
KW  - Prognostic scoring system
KW  - Societe Francaise
KW  - Gruppo-italiano
KW  - European group
KW  - Late mortality
KW  - Midollo-Osseo
KW  - LATE DEATHS
KW  - Survival
KW  - Blood
KW  - Ruxolitinib
Y1  - 2019
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-226386
VL  - 104
IS  - 9
ER  - 
TY  - JOUR
A1  - Wagner-Drouet, Eva
A1  - Teschner, Daniel
A1  - Wolschke, Christine
A1  - Schäfer-Eckart, Kerstin
A1  - Gärtner, Johannes
A1  - Mielke, Stephan
A1  - Schreder, Martin
A1  - Kobbe, Guido
A1  - Hilgendorf, Inken
A1  - Klein, Stefan
A1  - Verbeek, Mareike
A1  - Ditschkowski, Markus
A1  - Koch, Martina
A1  - Lindemann, Monika
A1  - Schmidt, Traudel
A1  - Rascle, Anne
A1  - Barabas, Sascha
A1  - Deml, Ludwig
A1  - Wagner, Ralf
A1  - Wolff, Daniel
T1  - Comparison of cytomegalovirus-specific immune cell response to proteins versus peptides using an IFN-γ ELISpot assay after hematopoietic stem cell transplantation
JF  - Diagnostics
N2  - Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality following hematopoietic stem cell transplantation (HSCT). Measuring CMV-specific cellular immunity may improve the risk stratification and management of patients. IFN-γ ELISpot assays, based on the stimulation of peripheral blood mononuclear cells with CMV pp65 and IE-1 proteins or peptides, have been validated in clinical settings. However, it remains unclear to which extend the T-cell response to synthetic peptides reflect that mediated by full-length proteins processed by antigen-presenting cells. We compared the stimulating ability of pp65 and IE-1 proteins and corresponding overlapping peptides in 16 HSCT recipients using a standardized IFN-γ ELISpot assay. Paired qualitative test results showed an overall 74.4% concordance. Discordant results were mainly due to low-response tests, with one exception. One patient with early CMV reactivation and graft-versus-host disease, sustained CMV DNAemia and high CD8\(^+\) counts showed successive negative protein-based ELISpot results but a high and sustained response to IE-1 peptides. Our results suggest that the response to exogenous proteins, which involves their uptake and processing by antigen-presenting cells, more closely reflects the physiological response to CMV infection, while the response to exogenous peptides may lead to artificial in vitro T-cell responses, especially in strongly immunosuppressed patients.
KW  - CMV
KW  - CMV-specific cellular immunity
KW  - hematopoietic stem cell transplantation
KW  - recall antigen
KW  - peptide
KW  - immune monitoring
KW  - IFN-γ ELISpot
KW  - T cells
KW  - antigen processing and presentation
KW  - immunosuppression
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-228843
SN  - 2075-4418
VL  - 11
IS  - 2
ER  -